Title : Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

Pub. Date : 2016

PMID : 26831200






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The antipsychotics brexpiprazole and cariprazine have been approved in the US, and although both are dopamine D2 receptor partial agonists, they differ markedly in their pharmacodynamic profiles. brexpiprazole dopamine receptor D2 Homo sapiens